|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hyperactive Shp2E76K mutant, commonly observed in leukemia patients, significantly accelerated MLL-AF9-mediated leukemogenesis in vivo.
|
25650089 |
2015 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The H3K4-specific demethylase KDM5B negatively regulates leukemogenesis in murine and human MLL-rearranged AML cells, demonstrating a crucial role for the H3K4 global methylome in determining LSC fate.
|
26190263 |
2015 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review focuses on the molecular mechanisms underlying MLL1 translocation-driven leukemogenesis and the latest progress on DOT1L-targeted epigenetic therapies for MLL1-rearranged and other leukemias.
|
26118503 |
2015 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study represents an important step for further defining the potential interplay between oncogenic molecules and reprogramming factors during MLL leukemogenesis.
|
24150221 |
2014 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings not only connect ELL to E2F1 function and uncover a novel role of ELL in response to DNA damage but also provide an insight into the mechanism for MLL-ELL-associated leukemogenesis.
|
24344198 |
2014 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SET domain-containing proteins such as MLL1 play a critical role in leukemogenesis, while others such as SETD2 may function as a tumor suppressor in breast cancer and renal cell carcinoma.
|
23065515 |
2013 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MLL(DNMT1 CXXC)-AF9 shows robust in vitro colony forming activity and in vivo leukemogenesis, similar to MLL-AF9.
|
23990460 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is poorly understood how MLL fusion proteins block differentiation, a hallmark of leukemogenesis.
|
23349306 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that PBX3 is a critical cofactor of HOXA9 in leukemogenesis, and targeting their interaction is a feasible strategy to treat presently therapy resistant CA-AML (eg, MLL-rearranged leukemia) in which HOXA/PBX3 genes are overexpressed.
|
23264595 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL-AF4 may be sufficient on its own for leukemogenesis or the gene-fusion product may alternatively predispose transformed cells to global genetic instability, enhancing the acquisition of additional key mutations.
|
23893660 |
2013 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we postulate that the inability of C/EBPα and GATA-1 to down-regulate DACH1 expression induced by MLL-AF9 during myeloid differentiation may contribute to t(9;11) leukemogenesis.
|
22902925 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the spectrum of MLL translocation partners in adult T-ALL much more resembles that of AML than that of BCP ALL and thus the mechanisms by which MLL contributes to leukemogenesis in adult T-ALL appear to differ from those in BCP ALL.
|
22927255 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo.
|
22516260 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
For instance, the MLL-AF9 fusion oncogene is thought to contribute to myeloid leukemogenesis by driving a hematopoietic stem cell-like "self-renewal" gene expression signature in committed myeloid progenitors.
|
22613471 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forced expression of miR-150 dramatically inhibited leukemic cell growth and delayed MLL-fusion-mediated leukemogenesis, likely through targeting FLT3 and MYB and thereby interfering with the HOXA9/MEIS1/FLT3/MYB signaling network, which in turn caused downregulation of MYC/LIN28.
|
23079661 |
2012 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several epigenetic regulators that modify DNA or histones have been implicated in MLL fusion driven leukemogenesis, including DNA methylation, histone acetylation, and histone methylation.
|
23054645 |
2012 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using an in vivo gene targeting approach, we demonstrate that Rac2, but not Rac1, is critical to the initiation of acute myeloid leukemia in a retroviral expression model of MLL-AF9 leukemogenesis.
|
21940819 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides its importance in endocrine organs, menin has been shown to interact with the mixed lineage leukemia (MLL) protein, a histone H3 lysine 4 methyltransferase, and plays a critical role in hematopoiesis and leukemogenesis.
|
21740816 |
2011 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Investigations in the past years on leukemogenesis and the MLL1-WDR5 histone H3Lys4 methyltransferase complex demonstrate that epigenetic regulation is one of the key steps in development and human diseases.
|
21439245 |
2011 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deletions of MLL that abolish interactions with PAFc also eliminate MLL-AF9 mediated immortalization indicating an essential function for this interaction in leukemogenesis.
|
20541477 |
2010 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that specific recruitment of MLL1 requires multiple interactions and is a precondition for stable recruitment of MLL1 fusion proteins to HoxA9 in leukemogenesis.
|
20541448 |
2010 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we discuss the potential molecular role of the PAFc in transcriptional dysregulation of MLL target genes and the interplay between PAFc and MLL-rearranged oncoproteins in leukemogenesis.
|
21037944 |
2010 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since CT45A2 is the first Cancer/Testis antigen family gene found fused with MLL in acute leukemia, future studies addressing its biologic relevance for leukemogenesis are warranted.
|
20920256 |
2010 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that concentrations of E2 and 4-OH-E2 that may occur during pregnancy, or during use of oral contraceptives, can cause aberrations of the MLL gene and could thus be a factor in the early events of leukemogenesis occurring in utero.
|
19264358 |
2009 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The identification and validation of consistent changes of gene expression in human and murine MLL rearrangement leukemias provide important insights into the genetic base for MLL-associated leukemogenesis.
|
19155294 |
2009 |